BioProton: Biologically relevant dose for Proton Therapy Planning

Lead Research Organisation: University of Manchester
Department Name: School of Medical Sciences

Abstract

Oxygen plays an important role in life on earth. The air that we breathe provides cells with the oxygen required for energy production. This need for oxygen increases for cells that rapidly multiply such as those associated with cancer; however, the supply is limited. As a tumour increases in size not all parts will be located near to vessels carrying oxygen rich blood. This results in a reduction in the oxygen levels in cells located furthest away from the blood vessel. It has been shown that these cells with low levels of oxygen (termed hypoxic) are more resistant to damage from radiation than those that are well oxygenated. This is also known to be the case for irradiation with protons. In proton therapy, a beam of protons is fired at the tumour in order to destroy the DNA in the cancerous cells, thus killing the tumour. The amount of energy and number of protons required to achieve this is determined by the tumour volume. Currently in proton therapy the tumour is irradiated such that the whole tumour volume receives the same dose (energy deposited per unit mass). If, however, parts of the irradiated tumour are more resistant to the radiation than others this technique of delivering a uniform dose across the tumour volume is not optimal.
The research planned in this project aims to address this through the use of computer modelling and imaging to produce a method of increasing the dose to those low-oxygen radiation-resistant parts of the tumour whilst delivering an appropriately lower dose to the well oxygenated regions. This advancement will improve proton beam therapy and benefit any patient undergoing this form of cancer treatment. The benefits will include increased chance of survival and fewer side effects associated with the treatment

Planned Impact

Advances in imaging and computing technology mean that PBT is an area, which has been developing exponentially, and the global market is expected to exceed $3bn by 2030. Although the UK has adopted PBT rather later than some countries it is in a good position to exploit this technology due to the recent investment of >£250M by NHS-England. The new NHS PBT clinical facility due to open at the Christie in Manchester in 2018, offers access to "state of the art technology" through a dedicated research room, within the clinical facility, that will occupy the 4th gantry space. This will be used entirely for research (it will not treat patients) and has a beamline rather than a clinical gantry. PBT is still a new technology and while it already offers significant benefits, if it is to achieve its full potential and deliver maximum advantage to patients (in terms of survival and quality of life) a number of scientific and technological challenges need to be addressed. BioProton considers the most intractable and arguably the most important of these challenges: how to deliver protons effectively to the most radiation resistant parts of the tumour and how to biologically optimise the dose so that it sterilises the whole tumour and its margins while causing minimal damage to surrounding healthy tissue.
This also opens a wealth of opportunities both to improve outcomes and quality of life for patients and develop new products, devices, software and services to benefit the UK economy and society. Through developing mathematical models which determine unique nano-dosimetric damage and repair parameters in hypoxic environments and imaging the tumour environment; BioProton offers the opportunity of biologically optimising the proton therapy plan and then delivering this plan using state of the art pencil beam scanning so the dose can be tailored to the tumour and weighted so that hypoxic, radiation resistant regions are given more dose. In this way more dose will be delivered to the tumour and resistant areas within it, while sparing the healthy tissue which surrounds it and minimising the dose to nearby sensitive organs at risk (OAR). Damage to normal tissue is normally the factor that limits the dose of radiation that can be used in radiotherapy. So reducing damage to normal tissue reduces both progressive side effects and the chances of secondary malignancies later in life. This is particularly important in children whose organs are more sensitive to radiation and because they are growing can experience severe side effects, which stay with them for life, if normal tissue damage is not minimised.
We believe that BioProton has the potential to deliver a paradigm change in PBT delivery and has been developed through an academic/clinical/industrial partnership. Working with Varian Medical we have already shown that we can incorporate nano-dosimetric parameters into their PBT planning system Eclipse. Don Whitley Scientific will help us develop the hypoxia cabinets needed to validate the models. By embedding BioProton in the clinical environment it will be informed by clinical priorities and its findings can be rapidly translated to the clinic through the translational elements of NIHR MBRC, CRUK MCRC and CRUK ART-NET grants. Our close working partnership with industry and NHS-England through the mentorship of Dr Crellin the national Clinical Lead for NHS-E Proton Therapy will ensure that BioProton is clinically focussed and has a route to policy makers in government. The existing EPSRC Network+ (EP/N027167) also facilitates this translation and our EU H2020 integrating activity INSPIRE widens the reach of the research as does our collaboration with Massachusetts General Hospital/ Harvard Medical School in USA. Likewise the links to PPRIG and CTRad provide a route for dissemination to patients and consumers and the wider clinical community.

Publications

10 25 50
publication icon
Biglin ER (2019) Preclinical dosimetry: exploring the use of small animal phantoms. in Radiation oncology (London, England)

publication icon
MacKay R (2021) FLASH radiotherapy: Considerations for multibeam and hypofractionation dose delivery. in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

 
Title Bragg peak glass 
Description working with a glassblower on a glass sculpture to represent the Bragg peak 
Type Of Art Artwork 
Year Produced 2020 
Impact this will form a piece of artwork 
 
Description Organised PTCOG 58 in 2019 which brought over 1350 people to Manchester and generated over £2.5M for the local economy
First results of mechanistic models incorporated in to Eclipse treatment plans
International inter-comparison of measurement of LET and how this can be incorporated in to treatment plans. This work has now been submitted for publication
Anonymised patient data available from PBT patients treated overseas and at the Christie being made available for BioProton
Hi-C data allows a new way of mapping DNA damage on to the genome, this is the first time that this has been done and is a new way of looking at chromosome aberations which is much more meaningful biologically.
Hi-C paper now published in PLOS computational biology
Hi-C now incorporated in to Topas-nBio open access
hypoxia cabinet with integrated robotic arm now operational in PBT bioprep room, extensive quality assurance and dossimetry measurements undertaken. Dosimetry variations are comparable to that on the clinical system (<3%). Defined a master equation to ensure reproducibility of measurements. Developed a capability for ultra high dose rate (FLASH) delivery where the dosimetry is within 5% (comparable to the best achievable anywhere in the world).
Conducted experiments with protons, FLASH protons under different oxygen tensions. Panels of cell lines have been studied. Results for individual cell lines are comparable under normoxia to the other study in this area.
Working to look at impact of hypoxia on DNA damage and repair. These results will be refined using Plasmid studies (where there is no repair) under different oxygen tensions before going on to studies in panels of cell lines.
Covid-19 has delayed PBT research room as the acceptance commissioning tests delayed and everything has to be done outside clinical hours. Covid restrictions in 2021 also impacted on the operation of the research room but not with the severity encountered in 2020.
Tracy Underwood who led the imaging WP4 left in September 2021 to take up a post in industry. Her imaging studies had been severely impacted by Covid and she had also had a period of maternity leave. However we have developed a collaboration with Dr Andy Macpartlin in the clinical proton centre who specialises in the treatment of head and neck cancers. These are often tumours with regions of hypoxia. Andy with colleagues at the Christie was pioneering the use of OE-MRI to examine the proton and photon patients he treats at the Christie. In a pilot study of 20 patients we are working with him and using OE-MRI with FMisoPET imaging to assess the volume and location of the hypoxic regions in each tumour. This will feed in to WP5 of Bioproton where a Dr Sam Ingram (50% NHS clinical scientist in proton centre and 50% PDRA) will look at how we can use biologically augmented treatment planning (from WP1-3) to dose escalate and treat these hypoxic regions. sam's work will also use the OE-MRI, FMisoPET and CT to look for digital fingerprints of hypoxia in the CT scans using machine learning and AI techniques.
Sam has just been awarded a Topol Digital Fellowship from Health Education England. These fellowships are awarded to support health professionals lead digital health transformations and innovations within their organisations. This is in response to The Topol Review, which the Secretary of State of Health and Social Care commissioned to provide guidance for the NHS to embrace emerging technologies such as genomics, digital medicine, robotics, and artificial intelligence. Sam's project will fit in the AI category and will be looking to clinically implement a machine learning model for the fast predictions of monte-carlo dose and linear-energy transfer in protons and fits in very well with the aims of Bioproton.
Since BioProton was funded the area of ultra high dose rate (FLASH) radiotherapy has been attracting world-wide interest. As hypoxia is very strongly linked to FLASH this is a perfect compliment to BioProton. Through the work of a PhD student we have been studying the parameter space where FLASH operates.
We have organised the world's first conference on FLASH radiotherapy and particle therapy. We planned to hold this in person in Vienna 1-3rd Dec 2021, but Covid made this impossible so we held it virtually. The conference attracted over 730 delegates from over 40 countries and the 2nd in the series will be held in Barcelona in 2022. 30 Nov - Dec 2nd.
Took part in Science Museum's Cancer Revolution Exhibition this opened at the Museum of Science and Industry in Manchester in October 2021 and transfers to Science Museum in London in March 2022. This work was also featured in The Guardian Dec 21 2021.
Exploitation Route biologically optimised treatment plans being developed
working with the clinical teams on hypoxia imaging - with pilot study involving 20 patients
International Conference FRPT
work from BioProton now available in Topas nBio available Open source
Science Musem Cancer Revolution Exhibition
Work featured at GM cancer conference and NCRI annual meeting
Sectors Healthcare,Government, Democracy and Justice,Culture, Heritage, Museums and Collections

URL https://bioproton-uat.e3c.dev/
 
Description POST note working with Science museum on new exhibit on PBT Cancer Revolution opened in Manchester in October 2021 and Transferring to London in 2022. This work was featured in The Guardian in Dec 21 2021 https://www.theguardian.com/cancer-revolutionaries/2021/dec/21/how-radiotherapy-became-a-lifesaver-from-x-rays-to-the-proton-beam PBT patient fact sheets with Brains Trust https://brainstrust.org.uk/brain-tumour-support/resources/downloads/pbt/ Meetings on development of UK PBT clinical trials TORPEDO, PARABLE, APPROACH. All of these trials have now been funded TORPEDO and a further trial PROTIS by CRUK. PARABLE and APPROACH by NIHR. PARABLE and PROTIS use biological augmented treatment planning from BioProton. Further trials being discussed framework agreement with varian looking at spinning out PBT research room end-stations and PBT research room. This has stalled due to Covid Development of a hypoxia cabinet with integrated robotic arm with Don Whitley Scientific. This is now complete and we are looking at an agreement with DWS if other groups wish to purchase BBC interview on FLASH radiotherapy work incorporated into NIH grant Topas n-Bio with MGH now available Open Source https://gray.mgh.harvard.edu/research/multi-scale-monte-carlo-modeling-lab/269-currently-under-development Developing relationship with IAEA on PBT Organised international conference on FLASH radiotherapy and particle therapy in 1-3 Dec 2021, over 730 people attended from over 40 countries International consensus on paper on LET and RBE paper published Working with clinicians and medical physicists at The Christie on how to implement outcomes of BioProton clinically Organised PTCOG58 in 2019 largest conference on particle therapy brought over 1350 people to Manchester from all over the world and generated £2.5M for local economy New patient cohort being imaged and results used in Bioproton and to inform future treatments Contributed to On cancer in 2021On Cancer is a new 44-page collection of research-led policy recommendations authored by academics from The University of Manchester, and The Christie which aim to highlight areas where research can inform policy changes and improve the lives of patients living with cancer. Started work with EMBRACE team on wearable devices, this involves clinicians from Manchester Foundation Trust and The Christie. A clinical trial has opened https://www.manchester.ac.uk/discover/news/trial-of-wearable-health-technology-for-cancer-patients-opens/
First Year Of Impact 2019
Sector Healthcare,Government, Democracy and Justice,Culture, Heritage, Museums and Collections
Impact Types Cultural,Societal,Economic,Policy & public services

 
Description Heavy Charged Particle Beam Therapy and related new Radiotherapy technologies: The Clinical Potential, Physics and Technical Developments Required to Deliver Benefit for Patients with Cancer
Geographic Reach National 
Policy Influence Type Participation in a national consultation
Impact 2 day meeting to look at clinical implications of heavy ion charged particle therapy and develop a road map. This is now published and formed the basis for the UK ITRF
URL https://www.research.manchester.ac.uk/portal/en/publications/heavy-charged-particle-beam-therapy-and...
 
Description Workstream 4 CoChair NCRI CTRad
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
Impact National body pioneering new developments in radiotherapy
URL https://www.ncri.org.uk/how-we-work/ctrad/
 
Description Cockcroft Phase 4 Award
Amount £7,772,375 (GBP)
Funding ID Cockcroft phase 4 
Organisation Science and Technologies Facilities Council (STFC) 
Sector Public
Country United Kingdom
Start 03/2021 
End 03/2025
 
Description Improving preclinical proton radiation dosimetry using a biologically relevant murine dosimetry phantom
Amount £121,654 (GBP)
Funding ID NC/W002256/1 
Organisation National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2022 
End 01/2024
 
Description Infrastructure in FLASH Radiotherapy
Amount £199,904 (GBP)
Funding ID RRNIA-Feb22\100002 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2022 
End 05/2024
 
Description Manchester RADNET
Amount £16,500,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2019 
End 09/2026
 
Description Modelling anomalous transport of nanoparticles and DNA repair to improve radiotherapy
Amount £702,576 (GBP)
Funding ID EP/V008641 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 03/2021 
End 03/2024
 
Description Proton FLASH
Amount £227,974 (GBP)
Organisation Varian Inc 
Sector Private
Country United States
Start 08/2019 
End 08/2021
 
Description Topol Digital Fellowship
Amount £20,000 (GBP)
Organisation Health Education England 
Sector Public
Country United Kingdom
Start 04/2022 
End 04/2023
 
Title Proton Therapy Research room in the clinical PBT centre at the Christie 
Description Research infrastructure to conduct research in proton therapy, funded by Christie Charity £5.6M. Over the past year we have been comissioning the research room and bioprep room. This has been slowed down due to Covid. first experiments March 2021 Experiments are now ongoing in the research room and the hypoxia cabinet with integrated robotic arm (designed with don Whitley Scientific) is now fully operational and performing high throughput experiments. Accurate QA and dosimetry < 3% comparable with clinical system achieved for protons. FLASH capability delivered, dosimetry <5% one of the best in the world. 
Type Of Material Improvements to research infrastructure 
Year Produced 2020 
Provided To Others? Yes  
Impact The plan is to make this research infrastructure available via UKRI and CRUK grants. The facility has to pay its own costs so funding would need to be applied for via competitive grants. CRUK now funding research room through RadNet as a national proton hub and have just funded a national FLASH infrastructure. 
URL https://protonsinspire.eu/facilities/the-christie-nhs-foundation-trust
 
Title Anonymisation of PBT overseas data and data from patients treated at The Christie with PBT 
Description Means to access anonymised patient data from PBT patients treated overseas and at the Christie. This allows real patient data to be used to validate models developed in BioProton and other UKRI grants 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? No  
Impact Means research outputs can be validated on real patient data 
 
Description IAEA PBT 
Organisation International Atomic Energy Agency
Country Austria 
Sector Charity/Non Profit 
PI Contribution international guidance on developing a PBT centre
Collaborator Contribution developing international guidance on training and workforce for governments or institutions wishing to develop a new PBT centre
Impact international guidance document being developed
Start Year 2019
 
Description Topas nBio 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Open access Topas-nBio software includes our research in the radiobiological gold standard
Collaborator Contribution Working together on joint projects and sharing research to incorporate in to Topas n-Bio
Impact Joint publications Joint abstract submission PTCOG, AAPM, FRPT New software release in Topas n-Bio
Start Year 2020
 
Description Varian Framework agreement 
Organisation Varian Inc
Country United States 
Sector Private 
PI Contribution All IP through the Framework agreement belong to UoM / Christie but Varian have first refusal to exploit. Strong collaboration working on LET and RBE., FLASH RT
Collaborator Contribution Varian have provided access to latest versions of Eclipse software through T boxes (fair market value $75k). We can bid to Varian through Framework agreement for funding for projects. Amount shown is $1USD as actual amount is commercial in confidence.
Impact Publications Abstracts to international conferences Talks at Varian events https://www.varian.com/resources-support/blogs/clinical-oncology-news/industryacademic-partnership-yields-fruit-ultra-high?mkt_tok=NzYwLURaTy0xNTUAAAF_91-kFzOl1w84B0apMtXzvKu7hkm8hlShdATmyb5CxEAbXxpP-tODhdQBFJCIUOJjlEcMr2KiIyBxtUvfhhqVLZLQdSC9Rv-XXQFbD0DZaSk
Start Year 2019
 
Title EMBRACE wearables clinical trial 
Description wearables for real time monitoring of cancer patients. A new trial opens in Greater Manchester today which is to test cutting-edge wearable technologies involving patients who have received cancer treatment. The commercially-available health sensors and devices produce a digital fingerprint of vital signs that could allow doctors to assess the progress of their patients. Called, EMBRaCE, (Enhanced Monitoring for Better Recovery and Cancer Experience), the trial is a collaboration between Manchester University NHS Foundation Trust, The Christie NHS Foundation Trust and The University of Manchester. The trial opens initially for blood cancer, lung, and colorectal cancer patients and will run across Greater Manchester. The technologies under investigation include: a smart ring, worn on any finger made by the company Oura the Withings ScanWatch, a hybrid smartwatch the Isansys system, which is worn on the chest. The technologies can assess a range of vital signs, including electrocardiogram (ECG), heart rate, temperature, physical activity levels and sleep. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2022
Development Status Under active development/distribution
Clinical Trial? Yes
UKCRN/ISCTN Identifier N/A
Impact Real time monitoring of patients. Has the potential of producing digital fingerprints to allow personalisation of treatment Cancer places a huge burden on the lives of people everywhere. This study uses cutting-edge technology that can monitor people during their treatment, with devices that they can wear all the time. We hope that it will provide new insights into how people cope with cancer treatment and what we can do to improve their recovery." This trial will assess if the latest wearable technology has a role in cancer care. "It will help us to identify ways that clinical staff can individualise treatment before, during, and after therapy. "We will find out if 24/7 data from these wearable sensors can be used to support patient recovery and provide accurate measurement outside clinic. "It could even support the development of new cancer treatments by developing a digital platform for clinical trials in cancer involving wearable devices or fitness trackers." 
URL https://www.manchester.ac.uk/discover/news/trial-of-wearable-health-technology-for-cancer-patients-o...
 
Title PARABLE Clinical Trial 
Description randomised Proton therapy clinical trial for breast cancer patients 
Type Therapeutic Intervention - Radiotherapy
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2022
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Bioproton is being used for the biologically augmented treatment planning in this trial 
 
Title RCT TORPEDO 
Description TORPEO RCT has been developed and is funded by CRUK, it started recruiting patients in Feb 2020 then paused due to Covid-19 and resumed again in late 2020 
Type Therapeutic Intervention - Radiotherapy
Current Stage Of Development Refinement. Clinical
Year Development Stage Completed 2022
Development Status Under active development/distribution
Clinical Trial? Yes
Impact First UK RCT in PBT 
URL https://www.ncri.org.uk/ncri-blog/the-journey-of-torpedo-the-uks-first-proton-beam-therapy-clinical-...
 
Title Topas nBio 
Description Since the open-source beta-release of TOPAS-nBio in 2019, the framework offers to connect energy deposition within irradiated cells (physics) via molecular reactions (chemistry) to cell kill/repair (biology) at the level of sub-cellular targets such as DNA. To facilitate the setup of simulations we further developed a Graphical User (GUI) Interface. TOPAS-nBio is an extension to TOPAS and layered on top of the Geant4/Geant4-DNA MC toolkit. The new release was built for TOPAS release 3.6 (based on Geant4.10.6.p3) and will be compatible with all future releases of TOPAS. First release in 2019 but our models incorporated 2020 onwards 
Type Of Technology Software 
Year Produced 2021 
Open Source License? Yes  
Impact The new features of TOPAS-nBio v1.0, offers improved modeling from initial DNA damage to cell outcome, Gold standard for radiobiology research 
URL https://topas-nbio.readthedocs.io/en/latest/getting-started/Members.html
 
Description Article in the Guardian newspaper Dec 2021 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact How radiotherapy became a lifesaver, advances in radiotherapy
https://www.theguardian.com/cancer-revolutionaries/2021/dec/21/how-radiotherapy-became-a-lifesaver-from-x-rays-to-the-proton-beam
Year(s) Of Engagement Activity 2021
URL https://www.theguardian.com/cancer-revolutionaries/2021/dec/21/how-radiotherapy-became-a-lifesaver-f...
 
Description BBC interview of FLASH radiotherapy 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact media interview for BBC on Flash proton therapy as part of CRUK RADNET launch
https://www.bbc.co.uk/news/uk-england-manchester-50289393
Year(s) Of Engagement Activity 2019
URL https://www.manchesterbrc.nihr.ac.uk/news-and-events/manchester-scientists-lead-way-next-generation-...
 
Description Film on proton therapy for GM cancer conference 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Film "what we have achieved in the last 12 months" which was shown during GM cancer conference. I also spoke at this conference
Year(s) Of Engagement Activity 2019
URL https://gmcancer.org.uk/greater-manchester-cancer-conference-2019/
 
Description Flash radiotherapy and Particle Therapy 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Development of a new international conference on FLASH in Dec 2021 with PCO Kenes and leading international reserchers. This conference was very successful and attracted over 730 people from 40 countries the 2nd in the series will be held in Barcelona Nov 30-Dec 2nd 2022.
the top 15 papers will be published in The Green Journal with further papers in Physica Medica where the abstracts will also be published
Year(s) Of Engagement Activity 2020,2021,2022
URL https://frpt-conference.org/
 
Description On cancer UoM and The Christie 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact On Cancer is a new 44-page collection of research-led policy recommendations authored by academics from The University of Manchester, and The Christie which aim to highlight areas where research can inform policy changes and improve the lives of patients living with cancer. It is a collaboration between the Manchester Cancer Research Centre, the Cancer Beacon, and the Policy@Manchester team at The University of Manchester and involves the thoughts and research activities of four CRUK RadNet Manchester affiliated radiotherapy researchers.

Specific relevant examples included in On Cancer relate to work by Professor Karen Kirkby and Professor Ananya Choudhury (Advanced radiotherapies: what are the challenges and opportunities). Here, Ananya and Karen argue that researchers need to work with policymakers to produce a cost-benefit analysis of MR-Linac and Proton Beam Therapies and engage with leadership to determine opportunities for informed and enhance patient consent.
As the recommendations have only been recently published, direct influence on policy is still unknown. The authors involved are all committed to helping to promote the activities of the articles further, and we are continuing to work with Policy@Manchester a team dedicated to connecting policymakers and researchers to further expand on these recommendations.
Year(s) Of Engagement Activity 2022
 
Description One day workshop on FLASH radiotherapy: Transforming Radiotherapy in a FLASH 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact One day workshop organised with NCRI CTRad to inform UK researchers about Flash radiotherapy
Year(s) Of Engagement Activity 2020
URL https://www.eventbrite.co.uk/e/transforming-radiotherapy-in-a-flash-tickets-84136780375#
 
Description POST Note 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact POST note for members of the House of commons and Lords
Advances in Cancer Treatment
Year(s) Of Engagement Activity 2019
URL https://researchbriefings.parliament.uk/ResearchBriefing/Summary/POST-PN-0598
 
Description PTCOG 58 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Largest conference ever held on particle therapy attracted over 1355 people to a 5.5 day event in Manchester and contributed over 2.5M to the local economy
Year(s) Of Engagement Activity 2019
URL https://ptcog58.org/
 
Description Talks for GM Cancer 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact GM cancer conference talking about proton therapy
link to the new PRECISE YouTube channel:
https://www.youtube.com/channel/UCTAyoUeLIYQu5Gokqle4-Pg/featured

And to the video:
https://www.youtube.com/watch?v=j2QR4PQvaeI
Year(s) Of Engagement Activity 2021
URL https://www.youtube.com/watch?v=j2QR4PQvaeI
 
Description You tube channel 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact You tube channel to promote research
Year(s) Of Engagement Activity 2021
URL https://www.youtube.com/channel/UCTAyoUeLIYQu5Gokqle4-Pg/featured
 
Description radiotherapy and me 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact event to listen to patients experience of radiotherapy
Year(s) Of Engagement Activity 2019
URL https://publicprogrammes.co.uk/radiotherapy-and-me